Author

L. Snell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Khimji· 1 shared A. Kurshan· 1 shared A. Pillai· 1 shared A. Waters· 1 shared B. Bertol· 1 shared C. Graham· 1 shared C. Mant· 1 shared D. Abd-Rabbo· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Khimji

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control

M. Guo, D. Abd-Rabbo, B. Bertol, M. Carew, S. Lukhele, L. Snell, W. Xu, G. Boukhaled, H. Elsaesser, M. J. Halaby, N. Hirano, T. McGaha, D. Brooks

This study identifies mechanisms by which CD4 T cell paralysis impairs tumor control by stalling proliferation and differentiation through Treg and CTLA4 signaling interactions.

bioRxiv · Apr 15, 2023 · PreprintCancer Biology

Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

J. Seow, Z. A. Shalim, C. Graham, S. Kimuda, A. Pillai, T. Lechmere, A. Kurshan, A. Khimji, L. Snell, G. Nebbia, C. Mant, A. Waters, J. Fox, M. H. Malim, K. J. Doores

The paper shows that vaccinated individuals develop broad neutralizing mAbs after Delta/BA.1 infection, but these mAbs are less effective against newer variants.

bioRxiv · Mar 30, 2023 · PreprintImmunology